The hard copies of 'Radiopharmaceutical Therapy' have arrived! Managed to get a pic with my Co-Editors…. The book really is the perfect stocking filler Lisa Bodei, MD, PhD The Zeglis Laboratory ☢️

Thank you, Jason!!! Such a fantastic endeavor! Without you and Brian it would never have been possible

Coming in the fall 2023. So proud to have been a part of this fantastic endeavor! Everything about RPT. Jason Lewis Radiochem MSK The Zeglis Laboratory ☢️

We will also have a tumor board focused on clinical applications of PSMA-targeted radioligand therapy. What an amazing panel including Michael Morris Lisa Bodei, MD, PhD Tuba Kendi Jeremie Calais. See what people think of cases like this. Looking forward to seeing everyone bright and early!

New Guideline Alert! Joint #SNMMI #EANM guideline for Lu-177 PSMA-targeted therapy will help practitioners select high-potential patients and prepare for clinical management. Thanks European Association of Nuclear Medicine (EANM)!
ow.ly/g7Ls50OKN8q #NuclearMedicine #RPTherapy #ProstateCancer

Excited to announce the release of the SNMMI consensus statement on PSMA RLT. We attempted to wrangle with a number of difficult questions about how to use PSMA RLT in clinical practice. Check it out at: jnm.snmjournals.org/content/early/…

Amazing Keynote by Lisa Bodei, MD, PhD before tonight’s opening ceremony #ISRS2023

Panelists are Dr.(s) Tara Masten, Caterina Ramogida, Danielle Vugts, and Lisa Bodei, MD, PhD!

1. For the first SNMMI Correlative Imaging Council case, Lisa Bodei, MD, PhD from Memorial Sloan Kettering Cancer Center presents a case of #PSMARLT where FDG PET, post-treatment SPECT and MRI all play a role in understanding response. Please watch the full video at bit.ly/3Bw5kDm.

A study published in JNM and led by Lisa Bodei, MD, PhD and Heiko Schöder found that blood-based biomarkers accurately predict neuroendocrine tumor response to radiopharmaceutical therapy. This study was selected as the featured article of the month: bit.ly/40YblEd

Using blood-based #biomarkers to determine the efficacy of ¹⁷⁷Lu-DOTATATE in #NeuroendocrineTumors . ow.ly/4PAF50NAttU

#NuclearMedicine #MedicalResearch #NETCancer Lisa Bodei, MD, PhD Diane Reidy-Lagunes Simone Krebs Laboratory Audrey Mauguen Richard K.G. Do

Blood-based genomic biomarkers are an aid to the application of theranostics of NETs, not an antagonistic technique!

Blood-based biomarkers accurately predict neuroendocrine tumor response to radiopharmaceutical therapy, according to a new study in JNM ow.ly/Q6FI50NCB8a

#NuclearMedicine #RPTherapy #NETCancer #JNuclMed

Now offering hybrid for our 2023 Imaging of Alimentary Tract cancers course May 8-9 in the beautiful NYC with experts from MSKCC and other renowned places! Spread the word! MSK CME marc gollub Iva Petkovska MD FSAR David D.B. Bates Yelena Y. Janjigian MD Lisa Bodei, MD, PhD

We made it to the cover of the JNM! What an honor! PPQ and NETest validation!

Thank you Nitya Raj, Simone Krebs, Richard Kinh Gian Do, Audrey Mauguen, Diane Reidy Lagunes and Heiko Schöder!

#JNM
#neuroendocrinetumors

In April JNM—FDA approval of Lecanemab…Buvat/Weber test ChatGPT…Chemotherapy and cognitive impairment…PRRT and NETs…AUC: Lymphoscintigraphy…Featured: PPQ/NETest validation for PRRT…[177Lu]Lu-ofatumumab lymphoma therapy ow.ly/1HJc50NAwj6 #NuclearMedicine #JNuclMed

Striving to improve the quality of SSR PET imaging interpretation. Thank you Gary Ulaner and Katherine Zukotynski for having us here! RSNA

Striving to improve the quality of SSR PET imaging interpretation. Thank you Gary Ulaner and Katherine Zukotynski for having us here! RSNA

Really enjoyed joining the panel for #prostatecancer Risk Stratification with distinguished colleagues James Eastham Anton Becker, MD, PhD Sigrid Carlsson Marie Carlo Lisa Bodei, MD, PhD

Lots of interesting angles and nuances in this space!

#MSKprostatecancerCME MSK CME

Lisa Bodei, MD, PhD shedding some light on molecular imaging and theranostics 💡
#MSKprostatecancerCME MSK CME